The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 28, 2014
Filed:
May. 19, 2004
Dianqing Wu, Chesire, CT (US);
Yazhou Zhang, Farmington, CT (US);
Peng Liu, West Hartford, CT (US);
Xiaofeng LI, West Hartford, CT (US);
Jie Zhang, Memphis, TN (US);
Jufang Shan, Memphis, TN (US);
Dean Engelhardt, New York, NY (US);
Dianqing Wu, Chesire, CT (US);
Yazhou Zhang, Farmington, CT (US);
Peng Liu, West Hartford, CT (US);
Xiaofeng Li, West Hartford, CT (US);
Jie Zhang, Memphis, TN (US);
Jufang Shan, Memphis, TN (US);
Dean Engelhardt, New York, NY (US);
Enzo Biochem, Inc., Farmingdale, NY (US);
University of Connecticut, Farmington, CT (US);
St. Jude's Childrens Hospital, Memphis, TN (US);
Abstract
The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.